Biotech Values

[DewDiligence]

HOW CROWDED IS THE CANCER-DRUG ARENA?

You be the judge. Here’s a partial list of cancer drugs in development:

Squalamine, MG-132, RWJ-417975, Atrasentan, ABX-EGF, anatumomab mafenatox, Exherin, Combidex, AVR118, Selone, Thiovir, AEG35156/GEM640, Neovastat, AGN193198, efaproxiral sodium, GivaRex, Abraxane, Mobist, Amplimexon, Amplizone, AMD- 3100, Dexosomes, ONCase, Oncophage, DMXAA, Gastrimmune, AP23841, AP23464, ARRY-142886 (AZD6244), ZD6126, ZD6474, SAHA, flavopiridol, AVE8062, Edotecarin, glufosfamide, BAY 43-9006, BAY 57-9352, BCX-1777, Clofarex, BST- 1005, Trimer, BIBF 1120, troponin I (TnI), BMS-184476, huJ591, Canvaxin, Multikine, GVAX, Xyotax, pixantrone, CDP 791, ThermoDox, EGF vaccine, IOR-C5, CEP-7055, rhAngiostatin,, rhEndostatin, CHIR 200131, CHIR258, ProMune, ARQ 501, exatecan mesylate, DE-310, ECO-02301, ECO-04601, ECO-02201, ABT-751, Prialt, Panzem, Eos 200-4 (M200), Thymitaq, FR901228, S2512, GTOP-99, HuMax- CD20, Genasense, TNFerade, GRN163, Elacridar, nelarabine, lapatinib ditosylate, 786034, SB485232, SB 497115, PT-523, IPdR, VEGF-2-mAb, GEM 220, Pentacea, ILX-651, eflornithine, isocoumarin, IMC-2C6, HF4-3C5, mAb 6.12, cantuzumab mertansine, SB-408075, huC242-DM1, EM-164, epratuzumab, labetuzumab, AFP-Cide-Y-90, IMMU-110, IMMU-106, 90Y-hPAM4, MX7091, MX7091, aminocandin, Onco TCS, mebendazole, Affinitac (LY900003), ISIS 16009, PE-38 (TP-38), Zarnestra, alkylade, O(6)-benzylguanine (BG), KRN633, KRN951, KOS- 862, geldanamycin, HumaRAD, AQ4N, UCN-01, KW-2170, LGD 1550, LGD1550, GTI 2040, aTm, Ceplene, MDX-214, EMD 72000, ZK-EPO, irofulven, MLN591DM1, MBT- 0206, MBT-0312, MPI-176716, MPC-6827, hIL13-PE38QQR, LE-SN38, DN-101, AEE788, NVP-ADW742, AAL-993 (ZK260255), vatalanib, HMN-214, OGX-225, OGX-320, Tarceva, combretastatin A-4 disodium phosphate (CA4DP), combretastatin A-4 prodrug (CA4P), Oxi-6197, Oxi 4503, 2C3, lasofoxifene, CP-547,632, PD-166866, AG- 013736, PD-0183812, canertinib dihydrochloride, Vidaza, Vectosome, PHY906, PT- 100, M-FP, phosphomannopentaose sulfate (PI-88), GMK, thrombospondin-1, Provecta, Reata 744 and 769, Reata 200, 300 and 400 series, VEGF Trap, RP101, SDX-101, SDX-102, Genexol-PM, Sarasar, SGN-30, SGN-40, S23906-1, Angiozyme, Tocosol Paclitaxel, SU9902, SU6668, SU011248, SNS-595, Dacogen, VEGF121 gelonin, LPD-PEG-Folate, LPD-PEG, Soblidotin, Telcyta, Prostvac-VF, rV- DF3/MUC-1, Fowlpox-CEA (6D)-TRICOM, vaccinia-CEA-TRICOM, Panvac-VF, chlorotoxin, TRU-015, TRU-016, GFB-111, curcubitacin I, GFB-116, Veglin, VGX- 100, VGX-110, CB001, anidulafungin, Triapine, cloretazine, Rencarex, WX-UK1, MAb K931, WX-G250RIT, WX-671, WX-678 series, WX-682 series, GPCR-uPAR, CCI- 779, interleukin-12 (IL-12), Xcellerate, XR5942/XR5944 series (MLN944), XR11612, OX40-OX40L, TheraCIM HR3, YM-1001, perifosine


Here’s a partial list of cancer drugs approved for marketing:

Aldara, Stemgen, Neulasta, Neupopeg, Arimidex, Zoladex, Nolvadex, Casodex, Faslodex, Iressa, Eligard (formerly Leuprogel), Leuprolide (Europe), Campto, Taxotere, Photofrin (North America), Photobarr (Europe), Modrenal, Modrefen, Rituxan (USA), MabThera (Europe), Zevalin, Taxol, Paraplatin, Trisenox, Bexxar, Quadramet, ProstaScint, Eloxatin/Eloxatine, Gemzar, Evista, Optruma (Europe, formerly Celvista), Alimta, Herceptin, Avastin, MedPulser, Aloxi (USA), Onicit (Europe), Alferon N Injection, Erbitux, Epogen (USA), Espo (Japan, China), Neupogen (USA, EU), Gran (Japan), Aranesp (USA), Nespo, Ontak (USA), Onzar (Europe), Targretin capsules, Targretin gel 1%, Avinza (formerly Morphelan), Ethyol, Ethiofos, Gammaphos, Velcade, Sandostatin; Sandostatin LAR Depot, Gleevec (USA), Glivec, Celebrex (formerly known as Celebra), Ribomustin, Cytostasan, Navelbine, Xeloda, Peg-Intron, Pegintron (Europe), TS-1, Cefaclor Extended Release, Dynepo


Source:
http://oncologyknowledgebase.net/updates/newdrug1Q04.html
http://oncologyknowledgebase.net/updates/markdrug1Q04.ht